市場調查報告書
商品編碼
966815

復發型多發性硬化症 (RRMS):流行病學的考察 (2030年)

Relapsing-Remitting Multiple Sclerosis (RRMS) - Epidemiology Insight - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球主要國家──美國,歐洲主要5個國家 (EU5:法國·德國·義大利·西班牙·英國) 、日本──的復發型多發性硬化症 (RRMS)的疫情趨勢與今後的預測分析。

目錄

第1章 主要考察

第2章 復發型多發性硬化症 (RRMS):摘要整理

第3章 復發型多發性硬化症 (RRMS):疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理生理學
  • 危險因素
  • 診斷標準

第4章 患者療程

第5章 流行病學和患者人口

  • 流行病學分析的要點
  • 假設和理論的根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 復發型多發性硬化症 (RRMS):主要7個國家的流行病學方案 (2017年∼2030年)
  • 美國的疫情趨勢
    • 美國國內的復發型多發性硬化症 (RRMS)的流行病學方案 (2017年∼2030年)
  • 歐洲5個國家:各國疫情趨勢
    • 德國的疫情趨勢
    • 法國的疫情趨勢
    • 義大利的疫情趨勢
    • 西班牙的疫情趨勢
    • 英國的疫情趨勢
  • 日本的疫情趨勢

第6章 治療流程,目前治療·診療方法

  • 復發型多發性硬化症 (RRMS)的治療·管理方法
  • 復發型多發性硬化症 (RRMS)的治療流程

第7章 產業學者 (KOL)的見解

第8章 未滿足需求

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1090

DelveInsight's 'Relapsing-Remitting Multiple Sclerosis (RRMS) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Relapsing-Remitting Multiple Sclerosis (RRMS) Understanding

The DelveInsight Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology report gives a thorough understanding of the Relapsing-Remitting Multiple Sclerosis (RRMS) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Relapsing-Remitting Multiple Sclerosis (RRMS) in the US, Europe, and Japan. The report covers the detailed information of the Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology scenario in seven major countries (US, EU5, and Japan).

Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Perspective by DelveInsight

The Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Relapsing-Remitting Multiple Sclerosis (RRMS) Detailed Epidemiology Segmentation

The Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology covered in the report provides historical as well as forecasted Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Relapsing-Remitting Multiple Sclerosis (RRMS) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Relapsing-Remitting Multiple Sclerosis (RRMS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Relapsing-Remitting Multiple Sclerosis (RRMS) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Relapsing-Remitting Multiple Sclerosis (RRMS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Relapsing-Remitting Multiple Sclerosis (RRMS)
  • The report provides the segmentation of the Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology

Report Highlights:

  • 11-Year Forecast of Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology
  • 7MM Coverage
  • Total Cases of Relapsing-Remitting Multiple Sclerosis (RRMS)
  • Total Cases of Relapsing-Remitting Multiple Sclerosis (RRMS) according to segmentation
  • Diagnosed cases of Relapsing-Remitting Multiple Sclerosis (RRMS)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Relapsing-Remitting Multiple Sclerosis (RRMS) ?
  • What are the key findings pertaining to the Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Relapsing-Remitting Multiple Sclerosis (RRMS) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Relapsing-Remitting Multiple Sclerosis (RRMS) ?
  • What are the currently available treatments of Relapsing-Remitting Multiple Sclerosis (RRMS) ?

Reasons to buy:

  • The Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Relapsing-Remitting Multiple Sclerosis (RRMS) market
  • Quantify patient populations in the global Relapsing-Remitting Multiple Sclerosis (RRMS) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Relapsing-Remitting Multiple Sclerosis (RRMS) therapeutics in each of the markets covered
  • Understand the magnitude of Relapsing-Remitting Multiple Sclerosis (RRMS) population by its epidemiology
  • The Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Relapsing-Remitting Multiple Sclerosis (RRMS)

3. Relapsing-Remitting Multiple Sclerosis (RRMS) : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment and Management
  • 6.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in 7MM (2017-2030)
  • Table 2: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in the United States (2017-2030)
  • Table 4: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Germany (2017-2030)
  • Table 6: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in France (2017-2030)
  • Table 8: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Italy (2017-2030)
  • Table 10: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Spain (2017-2030)
  • Table 12: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Japan (2017-2030)
  • Table 16: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in 7MM (2017-2030)
  • Figure 2: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in the United States (2017-2030)
  • Figure 4: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Germany (2017-2030)
  • Figure 6: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in France (2017-2030)
  • Figure 8: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Italy (2017-2030)
  • Figure 10: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Spain (2017-2030)
  • Figure 12: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Japan (2017-2030)
  • Figure 16: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report